See more : QMIS Finance Securities Corporation (QMIS) Income Statement Analysis – Financial Results
Complete financial analysis of PMV Pharmaceuticals, Inc. (PMVP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PMV Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Koito Manufacturing Co., Ltd. (KOTMF) Income Statement Analysis – Financial Results
- SG Corporation (004060.KS) Income Statement Analysis – Financial Results
- Bawan Company (1302.SR) Income Statement Analysis – Financial Results
- Maj Invest – Investeringsforeningsbevis (MAJEMV.CO) Income Statement Analysis – Financial Results
- Zhejiang Jihua Group Co., Ltd. (603980.SS) Income Statement Analysis – Financial Results
PMV Pharmaceuticals, Inc. (PMVP)
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| Gross Profit | -1.26M | -650.00K | -1.28M | -318.00K | -388.00K | -338.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.89M | 51.99M | 36.49M | 23.93M | 20.76M | 13.85M |
| General & Administrative | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Other Expenses | 0.00 | 87.00K | 21.00K | -143.00K | -8.00K | 16.00K |
| Operating Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Cost & Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Interest Income | 11.17M | 3.63M | 449.00K | 651.00K | 1.30M | 1.34M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| EBITDA | -78.88M | -76.73M | -57.99M | -34.62M | -26.25M | -18.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.13M | -77.04M | -58.29M | -34.94M | -26.64M | -18.89M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.17M | 3.71M | 470.00K | 508.00K | 1.29M | 1.36M |
| Income Before Tax | -68.96M | -73.33M | -57.82M | -34.43M | -25.34M | -17.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | -9.00K | 23.00K | 6.00K | 8.00K | 3.00K |
| Net Income | -68.96M | -73.32M | -57.85M | -34.44M | -25.35M | -17.54M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| EPS Diluted | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| Weighted Avg Shares Out | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
| Weighted Avg Shares Out (Dil) | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher...
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for...
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31,...
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the...
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
PRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a Phase 1 analysis reported promising anti-tumor activity...
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year...
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%....
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team. These include:
PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price
PMV Pharmaceuticals' phase 1/2 trial of its drug, PC14586, in solid tumors with a Y220C p53 mutation produced initial data in 2022, but the response was mixed. A 2023 update on data from the phase 1/2 trial is a net...
Source: https://incomestatements.info
Category: Stock Reports